Remove Imaging Remove Nuclear Medicine Remove Radiation Remove Radiopharmaceuticals
article thumbnail

ARRS: How to manage the side effects of radiopharmaceuticals

AuntMinnie

Three clinical issues that may arise with theranostics treatments will require special provisions, including spot imaging, according to insights shared during the 124th annual meeting of the American Roentgen Ray Society (ARRS) in Boston. It causes radiation injury that may be visible as dry desquamation or moist desquamation, for example.

article thumbnail

Illuminating the Future: Recent Breakthroughs in Nuclear Medicine Advancements (Maharashtra, Raigarh, Sangli, Satara, Sindhudurg, Solapur, Thane, Wardha, Washim, Yavatmal)

Future Teleradiology

Teleradiology-India Introduction: Nuclear medicine continues to be at the forefront of cutting-edge technologies, pushing the boundaries of diagnostic and therapeutic capabilities. Revolutionary Radioisotopes: Expanding the Diagnostic Toolkit: Explore the latest developments in novel radioisotopes used in nuclear medicine.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

IMV: PET scan volumes continue to grow

AuntMinnie

In terms of 2023 spending, the average radiopharmaceutical expenditure per fixed PET site is estimated to be $517,000. In 2023, 38% of PET systems were operated by the PET department, 28% by nuclear medicine, 24% by radiology/imaging, 5% by radiation oncology, and 2% by molecular imaging.

PET Scan 115
article thumbnail

RLS Radiopharmacies Partners with Eckert and Ziegler to Expand Production of Gallium-68-Based Radiopharmaceuticals

Imaging Technology

milla1cf Fri, 04/05/2024 - 11:31 April 5, 2024 — RLS Radiopharmacies , America’s only Joint Commission-accredited radiopharmacy network, today announced it has expanded its radiopharmaceutical contract development and manufacturing (rCDMO) capabilities by entering into a strategic agreement with global isotope technology leader Eckert & Ziegler.

article thumbnail

Perspective Therapeutics Announces Exclusive License Agreement with Mayo Clinic for New Radiopharmaceutical Platform for Prostate Cancer Treatment

Imaging Technology

This leading radiopharmaceutical platform provides detailed PET imaging-based diagnosis and dosimetry using long-lived copper-64 ( 64 Cu) for imaging and alpha-particle targeted RPT using lead-212 ( 212 Pb). It can also be used for beta-particle targeted RPT using copper isotopes.

article thumbnail

The rise of theranostics: Part 1 -- Gaining momentum

AuntMinnie

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval.

article thumbnail

The rise of theranostics: Part 2 -- Moving into communities

AuntMinnie

A decade ago, only a few radiopharmaceutical agents were used to help treat cancer patients. Even if some private urology, radiation oncology practices, or radiologist groups are building the ability to perform theranostics, experts are cautious about patient management, radiation safety, and the risk of unnecessary imaging.